Integrated Filing — IndAS



General information about company

Scrip Code 500420
NSE Symbol TORNTPHARM
MSEI Symbol NOTLISTED
ISIN INE685A01028
Name of company TORRENT PHARMACEUTICALS LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 22-05-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 09-05-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment Generic Formulation Business
Start date and time of board meeting 22-05-2026   14:00:00
End date and time of board meeting 22-05-2026   16:00:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? Yes
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication? Yes
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 13-02-2026
Indicate Company website link for updated RPT policy of the Company https://www.torrentpharma.com/docs/RPT_policy_2026_70b1353a45.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? Yes
No. of times funds raised during the quarter 1
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
No default on loans and debt securities



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 2,73,500.00 10,71,200.00
Other income 5,800.00 1,800.00
Total income 2,79,300.00 10,73,000.00
2 Expenses
(a) Cost of materials consumed 38,000.00 1,56,700.00
(b) Purchases of stock-in-trade 21,000.00 76,700.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (1,900.00) (2,200.00)
(d) Employee benefit expense 48,700.00 1,87,900.00
(e) Finance costs 22,500.00 34,100.00
(f) Depreciation, depletion and amortisation expense 19,700.00 76,400.00
(f) Other Expenses
1 Other Expenses 67,400.00 2,46,700.00
Total other expenses 67,400.00 2,46,700.00
Total expenses 2,15,400.00 7,76,300.00
3 Total profit before exceptional items and tax 63,900.00 2,96,700.00
4 Exceptional items (4,700.00) (7,000.00)
5 Total profit before tax 59,200.00 2,89,700.00
6 Tax expense
7 Current tax 7,200.00 72,000.00
8 Deferred tax 5,300.00 (1,500.00)
9 Total tax expenses 12,500.00 70,500.00
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 46,700.00 2,19,200.00
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 46,700.00 2,19,200.00
17 Other comprehensive income net of taxes (6,000.00) (14,700.00)
18 Total Comprehensive Income for the period 40,700.00 2,04,500.00
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 16,923.00 16,923.00
Face value of equity share capital 5 5
27 Details of debt securities
22 Reserves excluding revaluation reserve 8,28,300.00
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 13.8 64.75
Diluted earnings (loss) per share from continuing operations 13.8 64.75
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 13.8 64.75
Diluted earnings (loss) per share from continuing and discontinued operations 13.8 64.75
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 31-03-2026
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 3,33,600.00
Capital work-in-progress 38,400.00
Investment property 1,300.00
Goodwill 32,400.00
Other intangible assets 3,69,700.00
Intangible assets under development 3,600.00
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 13,04,600.00
Trade receivables, non-current 0.00
Loans, non-current 300.00
Other non-current financial assets
1 Other non-current financial assets 1,100.00
Total of other non-current financial assets 1,100.00
Total non-current financial assets 13,06,000.00
Deferred tax assets (net) 0.00
Other non-current assets
1 Other Tax Assets (net) 4,900.00
2 Other Non current assets 2,300.00
Total of other non-current assets 7,200.00
Total non-current assets 20,92,200.00
2 Current assets
Inventories 1,52,600.00
Current financial asset
Current investments 12,700.00
Trade receivables, current 2,64,100.00
Cash and cash equivalents 7,100.00
Bank balance other than cash and cash equivalents 1,200.00
Loans, current 500.00
Other current financial assets
Total of other current financial assets 14,700.00
Total current financial assets 3,00,300.00
Current tax assets (net) 0.00
Other current assets
1 Other current assets 36,200.00
Total of other current assets 36,200.00
Total current assets 4,89,100.00
3 Non-current assets classified as held for sale 100.00
4 Regulatory deferral account debit balances and related deferred tax Assets
Total assets 25,81,400.00
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 16,900.00
Other equity 8,28,300.00
Total equity attributable to owners of parent 8,45,200.00
Non controlling interest
Total equity 8,45,200.00
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 11,46,200.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities
1 Lease Liabilities 9,300.00
2 Other non-current financial liabilities 8,600.00
Total of other non-current financial liabilities 17,900.00
Total non-current financial liabilities 11,64,100.00
Provisions, non-current 36,800.00
Deferred tax liabilities (net) 76,300.00
Deferred government grants, Non-current
Other non-current liabilities
Total of other non-current liabilities
Total non-current liabilities 12,77,200.00
Current liabilities
Current financial liabilities
Borrowings, current 2,70,200.00
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 11,100.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 69,500.00
Total Trade payable 80,600.00
Other current financial liabilities
1 Lease Liabilities 1,900.00
2 Other current financial liabilities 71,700.00
Total of other current financial liabilities 73,600.00
Total current financial liabilities 4,24,400.00
Other current liabilities 6,500.00
1 Other current liabilities 6,500.00
Total of other current liabilities 6,500.00
Provisions, current 21,900.00
Current tax liabilities (Net) 6,200.00
Deferred government grants, Current
Total current liabilities 4,59,000.00
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 17,36,200.00
Total equity and liabilites 25,81,400.00
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-01-2026 01-04-2025
Date of end of reporting period 31-03-2026 31-03-2026
Whether results are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Amount of items that will not be reclassified to profit and loss 1,500.00 (600.00)
Total Amount of items that will not be reclassified to profit and loss 1,500.00 (600.00)
2 Income tax relating to items that will not be reclassified to profit or loss 200.00 (200.00)
3 Amount of items that will be reclassified to profit and loss
1 Amount of items that will be reclassified to profit and loss (9,700.00) (19,100.00)
Total Amount of items that will be reclassified to profit and loss (9,700.00) (19,100.00)
4 Income tax relating to items that will be reclassified to profit or loss (2,400.00) (4,800.00)
5 Total Other comprehensive income (6,000.00) (14,700.00)



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2025
B Date of end of reporting period 31-03-2026
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 2,89,700.00
Adjustments for reconcile profit (loss)
Adjustments for finance costs 34,100.00
Adjustments for decrease (increase) in inventories 3,400.00
Adjustments for decrease (increase) in trade receivables, current (37,900.00)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (12,200.00)
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current 0.00
Adjustments for other financial assets, current 0.00
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 3,100.00
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities (3,100.00)
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 76,400.00
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 0.00
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 0.00
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains 5,600.00
Adjustments for dividend income 10,000.00
Adjustments for interest income 300.00
Adjustments for share-based payments 0.00
Adjustments for fair value losses (gains) 0.00
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow (4,200.00)
Other adjustments to reconcile profit (loss) 100.00
Other adjustments for non-cash items 0.00
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) 55,000.00
Net cash flows from (used in) operations 3,44,700.00
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 71,600.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 2,73,100.00
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 12,62,200.00
Other cash receipts from sales of equity or debt instruments of other entities 900.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 4,100.00
Purchase of property, plant and equipment 51,000.00
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 10,000.00
Interest received 300.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash (1,200.00)
Net cash flows from (used in) investing activities (12,99,100.00)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 12,50,500.00
Repayments of borrowings 67,200.00
Payments of lease liabilities 2,600.00
Dividends paid 1,18,500.00
Interest paid 39,600.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities 10,22,600.00
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes (3,400.00)
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents (3,400.00)
Cash and cash equivalents cash flow statement at beginning of period 10,500.00
Cash and cash equivalents cash flow statement at end of period 7,100.00





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 BSR & Co. LLP Yes 31-07-2028


Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)

Amount in (Lakhs)

Mode of Fund Raising Others
Description of mode of fund raising (Applicable in case of others is selected)
Date of Raising Funds 19-01-2026
Amount Raised 10,99,000.00
Report filed for Quarter ended 31-03-2026
Monitoring Agency Not Applicable
Monitoring Agency Name, if applicable
Is there a Deviation / Variation in use of funds raised No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders
If Yes, Date of shareholder Approval
Explanation for the Deviation / Variation
Comments of the Audit Committee after review
Comments of the auditors, if any
Sr. Original Object Modified Object, if any Original Allocation Modified allocation, if any Funds Utilised Amount of Deviation/Variation for the quarter according to applicable object Remarks if any


Signatory Details

Name of signatory Chintan M Trivedi
Designation of person Company Secretary and Compliance Officer
Place Ahmedabad
Date 23-05-2026




Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Torrent Pharmaceuticals Limited Torrent Pharma Inc.(TPI), USA Wholly owned subsidiary Sale of goods or services - 43,628.00 92,586.00 97,188.00
2 Torrent Pharmaceuticals Limited Torrent Do Brazil Ltda. (TDBL), Brazil Wholly owned subsidiary Sale of goods or services - 34,674.00 31,677.00 48,329.00
3 Torrent Pharmaceuticals Limited Torrent Pharma Philippines Inc. (TPPI), Philippines Wholly owned subsidiary Sale of goods or services - 7,398.00 8,426.00 9,816.00
4 Torrent Pharmaceuticals Limited Laboratories Torrent (Malaysia) Sdn. Bhd., (LTM), Malaysia Wholly owned subsidiary Sale of goods or services - 2,378.00 2,584.00 1,667.00
5 Torrent Pharmaceuticals Limited ZAO Torrent Pharma (ZAO), Russia Wholly owned subsidiary Sale of goods or services - 5,685.00 7,531.00 8,205.00
6 Torrent Pharmaceuticals Limited Heumann Pharma GmbH & Co Generica KG, Germany Step down subsidiary Sale of goods or services - 21,165.00 14,893.00 19,884.00
7 Torrent Pharmaceuticals Limited Heunet Pharma GmbH, Germany Step down subsidiary Sale of goods or services - 1,580.00 1,706.00 1,187.00
8 Torrent Pharmaceuticals Limited Laboratorios Torrent S.A. de C.V. (LTSA), Mexico Wholly owned subsidiary Sale of goods or services - 2,196.00 5,916.00 5,606.00
9 Torrent Pharmaceuticals Limited Torrent Pharma (UK) Ltd (TPUK), UK Wholly owned subsidiary Sale of goods or services - 396.00 8,574.00 6,182.00
10 Torrent Pharmaceuticals Limited Torrent Pharma (Thailand) Co.Ltd., Thailand Wholly owned subsidiary Sale of goods or services - 298.00 310.00 341.00
11 Torrent Pharmaceuticals Limited Torrent Pharma (Malta) Limited Step down subsidiary Sale of goods or services - 70.00 89.00 43.00
12 Torrent Pharmaceuticals Limited Torrent Pharmaceuticals Chile SpA Wholly owned subsidiary Sale of goods or services - 55.00 0.00 56.00
13 Torrent Pharmaceuticals Limited Samir Mehta Key management personnel of entity or parent Remuneration 3,600.00 - 3,600.00 0.00 3,600.00
14 Torrent Pharmaceuticals Limited Aman Mehta Key management personnel of entity or parent Remuneration 1,275.00 - 1,275.00 0.00 500.00
15 Torrent Pharmaceuticals Limited Shaan Mehta Close Family Member of Key Management Personnel Remuneration 41.00 As per the terms of employment 41.00 0.00 0.00
16 Torrent Pharmaceuticals Limited Torrent Pharmaceuticals Ltd Employees Group Gratuity Scheme Trust set up by the Company for employee benefit plans Any other transaction Contribution to employee benefit plans 10,000.00 Total approval of Rs. 100 crores for contribution to employee benefit plans and advances 7,800.00 0.00 0.00
17 Torrent Pharmaceuticals Limited Torrent Pharmaceuticals Ltd Employees Group Gratuity Scheme Trust set up by the Company for employee benefit plans Advance 10,000.00 Total approval of Rs. 100 crores for contribution to employee benefit plans and advances 0.00 5.00 5.00 Advance 0 Repayable on demand Unsecured Gratuity payment to employees
18 Torrent Pharmaceuticals Limited Torrent Pharmaceuticals Ltd Employees Superannuation Scheme Trust set up by the Company for employee benefit plans Any other transaction Contribution to employee benefit plans 2,700.00 - 1,308.00 0.00 0.00
19 Torrent Pharmaceuticals Limited Torrent Investments Limited Parent Company Any other transaction Rent paid for leasing of land 48.00 - 24.00 0.00 0.00 Textual Information(1)
20 Torrent Pharmaceuticals Limited Torrent Investments Limited Parent Company Any other transaction Sale of Investment in Equity Shares of UNM Foundation 5.00 - 5.00 0.00 0.00
21 Torrent Pharmaceuticals Limited Torrent Australasia Pty Ltd. (TAPL), Australia Wholly owned subsidiary Purchase of goods or services - 52.00 8.00 6.00
22 Torrent Pharmaceuticals Limited J.B.Chemicals & Pharmaceuticals Limited Entity under Common Control Purchase of goods or services 1,300.00 - 236.00 0.00 277.00 Textual Information(2)
23 Torrent Pharmaceuticals Limited J.B.Chemicals & Pharmaceuticals Limited Entity under Common Control Dividend received - 9,951.00 0.00 0.00
24 Torrent Pharmaceuticals Limited Torrent Power Limited Fellow Subsidiary Purchase of goods or services 3,100.00 Total approval of Rs.31 Crores for purchase of electricity at applicable tariffs at various locations wherein Torrent Power Limited is the supplier of electricity including additional security deposits / Bank Guarantee, if any, to be given/ refunded / Interest Income accrued on total security deposits given / Purchase of any capital assets relating to Power consumption; 905.00 191.00 146.00
25 Torrent Pharmaceuticals Limited UNM Foundation Associate Any other transaction Contribution towards CSR activity 4,200.00 - 1,767.00 0.00 0.00
26 Torrent Pharmaceuticals Limited UNM Foundation Associate Any other transaction Contribution towards Donation 1,000.00 - 788.00 0.00 0.00
27 Torrent Pharmaceuticals Limited Torrent Australasia Pty Ltd. (TAPL), Australia Wholly owned subsidiary Any other transaction Expenses reimbursement - 4.00 1.00 0.00
28 Torrent Pharmaceuticals Limited Torrent Pharma (Malta) Limited Step down subsidiary Any other transaction Expenses reimbursement - 27.00 0.00 27.00
29 Torrent Pharmaceuticals Limited Torrent Pharma (Thailand) Co.Ltd., Thailand Wholly owned subsidiary Any other transaction Expenses reimbursement - 23.00 0.00 0.00
30 Torrent Pharmaceuticals Limited ZAO Torrent Pharma (ZAO), Russia Wholly owned subsidiary Any other transaction Expenses reimbursement - 34.00 0.00 35.00
31 Torrent Pharmaceuticals Limited Torrent Pharma Inc.(TPI), USA Wholly owned subsidiary Any other transaction Guarantee Commission Income - 386.00 273.00 283.00
32 Torrent Pharmaceuticals Limited Torrent Pharma Philippines Inc. (TPPI), Philippines Wholly owned subsidiary Any other transaction Guarantee Commission Income - 21.00 10.00 11.00
33 Torrent Pharmaceuticals Limited Torrent Electricals Limited Fellow Subsidiary Purchase of fixed assets 350.00 - 63.00 0.00 0.00 Textual Information(3)
34 Torrent Pharmaceuticals Limited Torrent Electricals Limited Fellow Subsidiary Any other transaction Receipt of Advance towards sale of Fixed Assets 100.00 - (90.00) 100.00 10.00
35 Torrent Pharmaceuticals Limited Torrent Electricals Limited Fellow Subsidiary Sale of fixed assets 4,402.00 - 4,089.00 0.00 0.00
36 Torrent Pharmaceuticals Limited Torrent Urja 27 Private Limited Step down subsidiary of holding company Investment 800.00 - 158.00 0.00 158.00
37 Torrent Pharmaceuticals Limited Torrent Green Energy Private Limited Step down subsidiary of holding company Any other transaction Lease rent income 42.00 - 42.00 0.00 45.00 Textual Information(4)
38 Torrent Pharmaceuticals Limited Torrent Green Energy Private Limited Step down subsidiary of holding company Any other transaction Recovery of expenses 4.00 - 4.00 0.00 5.00 Textual Information(5)
39 Torrent Pharmaceuticals Limited Torrent Pharma Inc.(TPI), USA Wholly owned subsidiary Any other transaction Guarantees (withdrawal)/ given (net) (including exchange rate variation) - 5,921.00 89,680.00 95,601.00
40 Torrent Pharmaceuticals Limited Torrent Pharma Philippines Inc. (TPPI), Philippines Wholly owned subsidiary Any other transaction Guarantees (withdrawal)/ given (net) (including exchange rate variation) - 234.00 3,552.00 3,786.00
41 Torrent Pharmaceuticals Limited Torrent Power Limited Fellow Subsidiary Any other transaction Guarantees given 0.00 Total approval of Rs.31 Crores for purchase of electricity at applicable tariffs at various locations wherein Torrent Power Limited is the supplier of electricity including additional security deposits / Bank Guarantee, if any, to be given/ refunded / Interest Income accrued on total security deposits given / Purchase of any capital assets relating to Power consumption; 0.00 312.00 312.00
42 Torrent Pharmaceuticals Limited Torrent Power Limited Fellow Subsidiary Any other transaction Security deposits given/ (refunded) (net) 0.00 Total approval of Rs.31 Crores for purchase of electricity at applicable tariffs at various locations wherein Torrent Power Limited is the supplier of electricity including additional security deposits / Bank Guarantee, if any, to be given/ refunded / Interest Income accrued on total security deposits given / Purchase of any capital assets relating to Power consumption; 0.00 20.00 20.00 Inter-corporate deposit 6.7500 - Unsecured As per Regulatory Requirement Textual Information(6)
43 Torrent Pharmaceuticals Limited Torrent Do Brazil Ltda. (TDBL), Brazil Wholly owned subsidiary Investment - 0.00 3,111.00 3,111.00
44 Torrent Pharmaceuticals Limited ZAO Torrent Pharma (ZAO), Russia Wholly owned subsidiary Investment - 0.00 5,880.00 5,880.00
45 Torrent Pharmaceuticals Limited ZAO Torrent Pharma (ZAO), Russia Wholly owned subsidiary Any other transaction Provision for diminition in value of investment - 0.00 2,308.00 2,308.00
46 Torrent Pharmaceuticals Limited Torrent Pharma GmbH (TPG), Germany Wholly owned subsidiary Investment - 0.00 2,337.00 2,337.00
47 Torrent Pharmaceuticals Limited Torrent Pharma Philippines Inc. (TPPI), Philippines Wholly owned subsidiary Investment - 0.00 475.00 475.00
48 Torrent Pharmaceuticals Limited Torrent Pharma Inc.(TPI), USA Wholly owned subsidiary Investment - 0.00 499.00 499.00
49 Torrent Pharmaceuticals Limited TPL (Malta) Limited Wholly owned subsidiary Investment - 5,404.00 22,857.00 28,261.00
50 Torrent Pharmaceuticals Limited Farmaceutica Torrent Colombia SAS, Colombia Wholly owned subsidiary Investment - 0.00 912.00 912.00
51 Torrent Pharmaceuticals Limited Torrent Pharmaceuticals Chile SpA Wholly owned subsidiary Investment - 0.00 825.00 825.00
52 Torrent Pharmaceuticals Limited Laboratorios Torrent S.A. de C.V. (LTSA), Mexico Wholly owned subsidiary Investment - 0.00 2,799.00 2,799.00
53 Torrent Pharmaceuticals Limited Torrent Australasia Pty Ltd. (TAPL), Australia Wholly owned subsidiary Investment - 0.00 30.00 30.00
54 Torrent Pharmaceuticals Limited Torrent Pharma (UK) Ltd (TPUK), UK Wholly owned subsidiary Investment - 0.00 168.00 168.00
55 Torrent Pharmaceuticals Limited Torrent Pharma (Thailand) Co.Ltd., Thailand Wholly owned subsidiary Investment - 0.00 2,096.00 2,095.00
56 Torrent Pharmaceuticals Limited Laboratories Torrent (Malaysia) Sdn. Bhd., (LTM), Malaysia Wholly owned subsidiary Investment - 0.00 77.00 77.00
57 Torrent Pharmaceuticals Limited Curatio Inc., Philippines Wholly owned subsidiary Investment - 0.00 1,583.00 1,583.00
58 Torrent Pharmaceuticals Limited Curatio Inc., Philippines Wholly owned subsidiary Any other transaction Provision for diminition in value of investment - 0.00 1,583.00 1,583.00
59 Torrent Pharmaceuticals Limited Torrent International Lanka (Pvt) Ltd., Srilanka Wholly owned subsidiary Investment - 0.00 915.00 915.00
60 Torrent Pharmaceuticals Limited Torrent International Lanka (Pvt) Ltd., Srilanka Wholly owned subsidiary Any other transaction Provision for diminition in value of investment - 0.00 915.00 915.00
61 Torrent Pharmaceuticals Limited UNM Foundation Associate Investment 5.00 - (5.00) 5.00 0.00
62 Heumann Pharma GmbH & Co Generica KG, Germany Torrent Pharma Inc.(TPI), USA Fellow Subsidiary of Holding company Loan - 0.00 26,638.00 28,396.00 Loan 4.7500 3 years, extendable Unsecured Business Purpose
63 Heumann Pharma GmbH & Co Generica KG, Germany Torrent Pharma Inc.(TPI), USA Fellow Subsidiary of Holding company Interest received - 641.00 344.00 333.00
64 Heumann Pharma GmbH & Co Generica KG, Germany Torrent Pharma (UK) Ltd (TPUK), UK Fellow Subsidiary of Holding company Loan - 0.00 14,084.00 14,825.00 Loan 5.2500 5 years, extendable Secured Business Purpose
65 Heumann Pharma GmbH & Co Generica KG, Germany Torrent Pharma (UK) Ltd (TPUK), UK Fellow Subsidiary of Holding company Interest received - 373.00 199.00 187.00
66 Heumann Pharma GmbH & Co Generica KG, Germany Heunet Pharma GmbH, Germany Fellow Subsidiary Sale of goods or services - 70.00 0.00 0.00
67 Heumann Pharma GmbH & Co Generica KG, Germany Heunet Pharma GmbH, Germany Fellow Subsidiary Purchase of goods or services - 91.00 0.00 0.00
68 Heumann Pharma GmbH & Co Generica KG, Germany Torrent Pharma (UK) Ltd (TPUK), UK Fellow Subsidiary of Holding company Purchase of goods or services - 0.00 77.00 0.00
69 Heumann Pharma GmbH & Co Generica KG, Germany Torrent Pharma (UK) Ltd (TPUK), UK Fellow Subsidiary of Holding company Any other transaction Recovery of expenses - 9.00 0.00 7.00
70 Heumann Pharma GmbH & Co Generica KG, Germany Torrent Pharma GmbH (TPG), Germany Parent Company Any other transaction Expenses reimbursement - 0.00 0.00 0.00
71 Heumann Pharma GmbH & Co Generica KG, Germany Torrent Pharma GmbH (TPG), Germany Parent Company Any other transaction Receivable towards Corporate tax balances setoff in Group Tax filing - 23.00 108.00 23.00
72 Heumann Pharma GmbH & Co Generica KG, Germany Heunet Pharma GmbH, Germany Fellow Subsidiary Any other transaction Recovery of expenses - 4,015.00 0.00 4,849.00
73 Heumann Pharma GmbH & Co Generica KG, Germany Torrent Pharma (Malta) Limited Subsidiary of Fellow Subsidiary Purchase of goods or services - 2,947.00 0.00 195.00
74 Torrent Pharma GmbH (TPG), Germany Heumann Pharma GmbH & Co Generica KG, Germany Wholly owned subsidiary Investment - 0.00 3,104.00 3,104.00
75 Torrent Pharma GmbH (TPG), Germany Heunet Pharma GmbH, Germany Wholly owned subsidiary Investment - 0.00 17.00 17.00
76 TPL (Malta) Limited Torrent Pharma (Malta) Limited Wholly owned subsidiary Investment - 5,296.00 22,819.00 28,115.00
77 Unique Pharmaceutical Laboratories FZE, Dubai JBCPL Philippines Inc Entity under Common Control Interest received - 1.00 9.00 10.00 Textual Information(7)
78 Unique Pharmaceutical Laboratories FZE, Dubai JBCPL Philippines Inc Entity under Common Control Loan - 0.00 101.00 115.00 Loan 6.0500 Repayable on demand Unsecured Working capital Textual Information(8)
79 Unique Pharmaceutical Laboratories FZE, Dubai JBCPL Philippines Inc Entity under Common Control Investment - 0.00 178.00 178.00 Textual Information(9)
80 Unique Pharmaceutical Laboratories FZE, Dubai Biotech Laboratories (Pty) Ltd, South Africa Entity under Common Control Investment - 0.00 9,186.00 9,186.00 Textual Information(10)
81 J.B.Chemicals & Pharmaceuticals Limited OOO Unique Pharmaceutical Laboratories, Russia Entity under Common Control Investment - 0.00 3,882.00 3,882.00 Textual Information(11)
82 J.B.Chemicals & Pharmaceuticals Limited Unique Pharmaceutical Laboratories FZE, Dubai Entity under Common Control Investment - 0.00 10,406.00 10,406.00 Textual Information(12)
83 J.B.Chemicals & Pharmaceuticals Limited OOO Unique Pharmaceutical Laboratories, Russia Entity under Common Control Sale of goods or services 6,500.00 - 797.00 5,290.00 3,605.00 Textual Information(13)
84 J.B.Chemicals & Pharmaceuticals Limited OOO Unique Pharmaceutical Laboratories, Russia Entity under Common Control Any other transaction Marketing Service Fees paid 3,221.00 - 618.00 1,697.00 616.00 Textual Information(14)
85 J.B.Chemicals & Pharmaceuticals Limited OOO Unique Pharmaceutical Laboratories, Russia Entity under Common Control Any other transaction Guarantee Commission 2,000.00 - 0.00 12.00 12.00 Textual Information(15)
86 J.B.Chemicals & Pharmaceuticals Limited OOO Unique Pharmaceutical Laboratories, Russia Entity under Common Control Any other transaction Recovery of expenses 2,500.00 - 0.00 15.00 15.00 Textual Information(16)
87 J.B.Chemicals & Pharmaceuticals Limited Unique Pharmaceutical Laboratories FZE, Dubai Entity under Common Control Sale of goods or services 1,800.00 - 0.00 435.00 453.00 Textual Information(17)
88 J.B.Chemicals & Pharmaceuticals Limited Unique Pharmaceutical Laboratories FZE, Dubai Entity under Common Control Any other transaction Compensation cost- ESOP 123.00 - 0.00 297.00 305.00 Textual Information(18)
89 J.B.Chemicals & Pharmaceuticals Limited Unique Pharmaceutical Laboratories FZE, Dubai Entity under Common Control Any other transaction Compensation cost- ESOP 120.00 - 0.00 391.00 407.00 Textual Information(19)
90 J.B.Chemicals & Pharmaceuticals Limited Unique Pharmaceutical Laboratories FZE, Dubai Entity under Common Control Any other transaction Marketing Support Service 770.00 - 103.00 100.00 36.00 Textual Information(20)
91 J.B.Chemicals & Pharmaceuticals Limited JBCPL Philippines Inc Entity under Common Control Any other transaction Transfer of Certificate of Product registration (CPR) 65.00 - 0.00 28.00 29.00 Textual Information(21)
92 J.B.Chemicals & Pharmaceuticals Limited Biotech Laboratories (Pty) Ltd, South Africa Entity under Common Control Sale of goods or services 9,950.00 - 1,119.00 1,765.00 688.00 Textual Information(22)
93 J.B.Chemicals & Pharmaceuticals Limited Biotech Laboratories (Pty) Ltd, South Africa Entity under Common Control Any other transaction Technical Service fee and DAP charges 500.00 - 100.00 37.00 70.00 Textual Information(23)
94 J.B.Chemicals & Pharmaceuticals Limited Dadra and Nagar Haveli and Daman and Diu Power Distribution Corporation Limited Entity under Common Control Any other transaction Purchase of electricity 156.00 - 156.00 0.00 0.00 Textual Information(24)
95 J.B.Chemicals & Pharmaceuticals Limited Dadra and Nagar Haveli and Daman and Diu Power Distribution Corporation Limited Entity under Common Control Any other transaction Fixed Deposit - 0.00 0.00 66.00 Textual Information(25)
96 J.B.Chemicals & Pharmaceuticals Limited Dadra and Nagar Haveli and Daman and Diu Power Distribution Corporation Limited Entity under Common Control Any other transaction Bank Guarantee - 0.00 0.00 347.00 Textual Information(26)
Total value of transaction during the reporting period 1,79,949.00



Text Block

Textual Information(1) excluding Goods and Services Tax.
Textual Information(2) Value of transaction is excluding Goods and Services Tax.
Textual Information(3) excluding Goods and Services Tax.
Textual Information(4) Value of transaction is excluding Goods and Services Tax.
Textual Information(5) Value of transaction is excluding Goods and Services Tax.
Textual Information(6) Deposit as per Regulatory requirement. Interest rate % is as determined by Regulatory authority from time to time.
Textual Information(7) Op. balance as on 21st Jan,2026 since control was aquired on 21st Jan,2026
Textual Information(8) Op. balance as on 21st Jan,2026 since control was aquired on 21st Jan,2026
Textual Information(9) Op. balance as on 21st Jan,2026 since control was aquired on 21st Jan,2026
Textual Information(10) Op. balance as on 21st Jan,2026 since control was aquired on 21st Jan,2026
Textual Information(11) Op. balance as on 21st Jan,2026 since control was aquired on 21st Jan,2026
Textual Information(12) Op. balance as on 21st Jan,2026 since control was aquired on 21st Jan,2026
Textual Information(13) Op. balance as on 21st Jan,2026 since control was aquired on 21st Jan,2026
Textual Information(14) Op. balance as on 21st Jan,2026 since control was aquired on 21st Jan,2026
Textual Information(15) Op. balance as on 21st Jan,2026 since control was aquired on 21st Jan,2026
Textual Information(16) Op. balance as on 21st Jan,2026 since control was aquired on 21st Jan,2026
Textual Information(17) Op. balance as on 21st Jan,2026 since control was aquired on 21st Jan,2026
Textual Information(18) Op. balance as on 21st Jan,2026 since control was aquired on 21st Jan,2026
Textual Information(19) Op. balance as on 21st Jan,2026 since control was aquired on 21st Jan,2026
Textual Information(20) Op. balance as on 21st Jan,2026 since control was aquired on 21st Jan,2026
Textual Information(21) Op. balance as on 21st Jan,2026 since control was aquired on 21st Jan,2026
Textual Information(22) Op. balance as on 21st Jan,2026 since control was aquired on 21st Jan,2026
Textual Information(23) Op. balance as on 21st Jan,2026 since control was aquired on 21st Jan,2026
Textual Information(24) Op. balance as on 21st Jan,2026 since control was aquired on 21st Jan,2026
Textual Information(25) Op. balance as on 21st Jan,2026 since control was aquired on 21st Jan,2026
Textual Information(26) Op. balance as on 21st Jan,2026 since control was aquired on 21st Jan,2026